8377903

The Federal Circuit affirmed a lower tribunal's ruling of unpatentability for US8377903B2, rendering the patent invalid and unenforceable.

The Delaware District Court entered final judgment in favor of Hopewell Pharma Ventures, Inc., invalidating claims of US8377903 (among other patents) as obvious.

The court entered judgment entirely in favor of Apotex, declaring claims 17, 19, 20, and 22–27 of the '903 patent (among others) invalid as obvious and dismissing all of Merck's infringement claims.